|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123792 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-29 17:40:38 |
|
注册时间: Date of Registration: |
2026-04-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
纤维蛋白胶与氰基丙烯酸酯胶治疗直接或即将发生的角膜穿孔:一项随机对照试验 |
|
Public title: |
Fibrin glue versus Cyanoacrylate glue in the management of frank or impending corneal perforation: A Randomized Control Trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
纤维蛋白胶与氰基丙烯酸酯胶治疗直接或即将发生的角膜穿孔:一项随机对照试验 |
|
Scientific title: |
Fibrin glue versus Cyanoacrylate glue in the management of frank or impending corneal perforation: A Randomized Control Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
AIMEN QAMAR KHAN |
研究负责人: |
AIMEN QAMAR KHAN |
|
Applicant: |
AIMEN QAMAR KHAN |
Study leader: |
AIMEN QAMAR KHAN |
|
申请注册联系人电话: Applicant telephone: |
+92 307 0607964 |
研究负责人电话:
Study leader's |
+92 307 0607964 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hijabkhan411@gmail.com |
研究负责人电子邮件: Study leader's E-mail: |
hijabkhan411@gmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
梅奥医院,爱德华国王医科大学,Shahrah-e-Quaid-e-Azam(广场),拉合尔,旁遮普省,巴基斯坦. |
研究负责人通讯地址: |
梅奥医院,爱德华国王医科大学,Shahrah-e-Quaid-e-Azam(广场),拉合尔,旁遮普省,巴基斯坦. |
|
Applicant address: |
Mayo Hospital, King Edward Medical University, Shahrah-e-Quaid-e-Azam (The Mall), Lahore, Punjab, Pakistan. |
Study leader's address: |
Mayo Hospital, King Edward Medical University, Shahrah-e-Quaid-e-Azam (The Mall), Lahore, Punjab, Pakistan. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
拉合尔爱德华国王医学院/梅奥医院 |
||
|
Applicant's institution: |
King Edward Medical University/ Mayo Hospital, Lahore |
||
|
研究负责人所在单位: |
拉合尔爱德华国王医学院/梅奥医院 |
||
|
Affiliation of the Leader: |
King Edward Medical University/ Mayo Hospital, Lahore |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
No. 173/RC/KEMU |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
爱德华国王医学院机构审查委员会 |
||
|
Name of the ethic committee: |
Institutional review board, king Edward medical university |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-25 00:00:00 | ||
|
伦理委员会联系人: |
Institutional review board, king Edward medical university |
||
|
Contact Name of the ethic committee: |
Institutional review board, king Edward medical university |
||
|
伦理委员会联系地址: |
梅奥医院,爱德华国王医科大学,Shahrah-e-Quaid-e-Azam(广场),拉合尔,旁遮普省,巴基斯坦. |
||
|
Contact Address of the ethic committee: |
Mayo Hospital, King Edward Medical University, Shahrah-e-Quaid-e-Azam (The Mall), Lahore, Punjab, Pakistan. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+92 42 99214819 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
拉合尔爱德华国王医学院/梅奥医院 |
||||||||||||||||||||||
|
Primary sponsor: |
King Edward Medical University/ Mayo Hospital, Lahore |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
梅奥医院,爱德华国王医科大学,Shahrah-e-Quaid-e-Azam(广场),拉合尔,旁遮普省,巴基斯坦。 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Mayo Hospital, King Edward Medical University, Shahrah-e-Quaid-e-Azam (The Mall), Lahore, Punjab, Pakistan. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
角膜穿孔 |
||||||||||||||||||||||
|
Target disease: |
Corneal perforation |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较纤维蛋白胶与氰基丙烯酸酯胶治疗角膜穿孔的疗效及不良反应的发生情况。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the fibrin glue with cyanoacrylate glue for the management of corneal perforation in terms of effectiveness and occurrence of side effects. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 年龄 18-85 岁 2. 严重角膜变薄或穿孔,大小不超过 3mm |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age 18-85 years 2. Severe corneal thinning or perforation of size 3mm or less |
||||||||||||||||||||||
|
排除标准: |
1. 既往曾接受针对角膜变薄或穿孔的手术干预,如结膜瓣、板层移植、羊膜移植。 2. 角膜移植片(角膜成形术)上出现严重变薄或穿孔。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Previous surgical intervention for corneal thinning or perforation such as conjuctival flap, tectonic graft, amniotic membrane graft. 2. Severe thinning or perforation in a corneal graft (keratoplasty). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-01 00:00:00至 To 2026-11-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2026-11-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用抛硬币法将患者分为氰基丙烯酸酯组和纤维蛋白胶组。如果一组的样本量比另一组先达到,则将剩余的患者进入第二组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The patients will be allocated either cyanoacrylate or fibrin glue group by flip coin method. If sample size of one group is achieved before the other one, the remaining patients will be entered to second group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不会被共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Will not be shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
所有在拉合尔梅奥医院眼科研究所就诊并符合纳入要求的患者将在机构审查委员会批准后加入研究。将采取知情的书面同意。采用抛硬币法将患者分为氰基丙烯酸酯组和纤维蛋白胶组。如果一组的样本量比另一组先达到,则将剩余的患者进入第二组。经过详细检查(视力、裂隙灯、赛德尔试验)后,将胶水涂在角膜穿孔处。视力、裂隙灯检查和西德尔试验将在第0、1、7和30天重复进行。如果赛德尔试验在第0、1或7天呈阳性,则需要重新涂胶。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All the patients presenting in the institute of ophthalmology, Mayo hospital, Lahore, and meeting the inclusion requirements will be added to the study following Institutional Review Board approval. Informed written consent will be taken. The patients will be allocated either cyanoacrylate or fibrin glue group by flip coin method. If sample size of one group is achieved before the other one, the remaining patients will be entered to second group. After detailed examination (visual acuity, slit lamp, siedel test), glue will be applied to the area of corneal perforation. Visual acuity, Slit lamp examination and siedel test will be repeated at day 0, 1, 7 and 30. If seidel test is positive at day 0, 1 or 7, glue will be reapplied. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |